Special Issue

Theranostic Radiopharmaceuticals: Current Status and Perspectives

Message from the Guest Editor

Theranostics are nano-sized or molecular-level agents serving both diagnosis and therapy. Structurally, they are drug delivery systems integrated with molecular or targeted imaging agents. Theranostics are becoming popular because they are targeted therapeutics and can be used with no or minimal changes for diagnostic imaging to aid in precision medicine. Theranostics in nuclear medicine includes the use and application of two identical or very closely related radiopharmaceuticals for therapy and diagnosis. In oncology, tumor-specific substrates, receptor ligands, or drugs can serve as leads for theranostic development when labeled with specific radionuclides for imaging or therapy. I am pleased to invite you to contribute a manuscript to this Special Issue, "Theranostic radiopharmaceuticals: current status and perspectives". The goal of this Special Issue is to present the development of new drugs for theranostic applications, where imaging and therapeutic molecules should be parts of a single platform functionalized with various moieties for the specific recognition of molecular targets, imaging markers, and therapeutic compounds.

Guest Editor

Prof. Dr. Tatjana P. Stanojković

Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia

Deadline for manuscript submissions

closed (31 December 2024)

Pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).